Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Company Contact | |
Address: | 18 Hook Ave, Unit 101 TORONTO ON M6P 1T4 |
Tel: | 1-416-6691001 |
Website: | https://www.ventripoint.com |
IR: | See website |
Key People | ||
George Adams Executive Chairman of the Board | Alvira Macanovic President, Chief Executive Officer | Jimmy Jeon Chief Financial Officer |
Business Overview |
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company's Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart's structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system's proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI). |
Financial Overview |
For the fiscal year ended 31 December 2023, VentriPoint Diagnostics Ltd. revenues decreased 28% to C$49K. Net loss remained flat at C$4.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income reflects General and administrative decrease of 9% to C$2.8M (expense), Net Financing Income/Expense increase from C$1K to C$46K (income). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $33.68M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.05M as of Dec 31, 2023 |
EBITDA (TTM): | -$4.86M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.87M as of Dec 31, 2023 |
Free cash flow (TTM): | -$3.80M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 157,182,655 as of Feb 6, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |